HOMA-IR: How to Interpret Your Result

By
Published Updated Last reviewed
Medical lab testing image for HOMA-IR: How to Interpret Your Result

At a glance

  • Formula / (Fasting insulin [µIU/mL] × Fasting glucose [mmol/L]) ÷ 22.5
  • Optimal range / below 1.0 (high insulin sensitivity)
  • Normal adult range / 1.0 to 1.9
  • Insulin resistance threshold / 2.0 or above
  • High-risk threshold / 2.9 or above (AACE position)
  • Test type / calculated from two fasting blood values
  • Fasting requirement / 8 to 12 hours before draw
  • Primary use / screening for insulin resistance, prediabetes risk stratification
  • Limitation / not validated for patients already on insulin therapy

What Is HOMA-IR and How Is It Calculated?

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It estimates how resistant your cells are to insulin using just two fasting lab values: fasting serum insulin and fasting plasma glucose. The formula, published by Matthews and colleagues in 1985 and still in routine use, is: (fasting insulin in µIU/mL multiplied by fasting glucose in mmol/L) divided by 22.5. [1]

The Biology Behind the Score

Insulin is the key that opens cell membranes to glucose. When cells become resistant, the pancreas compensates by secreting more insulin to maintain normal blood sugar. Because both values rise together before fasting glucose climbs into the diabetic range, HOMA-IR can flag a problem years before a standard HbA1c test does. [2]

Unit Conversion

Most U.S. Labs report glucose in mg/dL rather than mmol/L. To convert: divide mg/dL by 18.0. A fasting glucose of 90 mg/dL equals 5.0 mmol/L. Plugging in a fasting insulin of 8 µIU/mL and a fasting glucose of 5.0 mmol/L gives a HOMA-IR of (8 × 5.0) ÷ 22.5 = 1.78.

Validation Record

The original 1985 HOMA paper has accumulated over 5,000 citations and has been validated against the hyperinsulinemic-euglycemic clamp, the gold-standard direct measure of insulin sensitivity. A 2004 update by Wallace et al. (HOMA2) improved accuracy by modeling variable insulin secretion and hepatic insulin clearance, and the HOMA2 calculator is freely available from the Oxford Centre for Diabetes. [3]

What Is a Normal HOMA-IR Range?

Reference ranges differ slightly across populations and laboratories, but the values below reflect consensus from the American Association of Clinical Endocrinology (AACE) and published population studies. [4]

Accepted Thresholds in Non-Diabetic Adults

  • Below 1.0: optimal insulin sensitivity. Athletes and lean individuals often land here.
  • 1.0 to 1.9: within the normal adult range for most Western populations.
  • 2.0 to 2.9: early or moderate insulin resistance. Risk for prediabetes and metabolic syndrome rises meaningfully in this band.
  • 2.9 or above: clinically significant insulin resistance. The AACE 2022 Consensus Statement on Insulin Resistance uses approximately this cut-point to define actionable resistance in non-diabetic adults. [4]

Population Context Matters

A 2010 analysis of 3,946 non-diabetic adults from the NHANES dataset found a median HOMA-IR of 2.1 (95th percentile: 6.0) in U.S. Adults, which is higher than European cohorts where medians fall closer to 1.4 to 1.7. [5] This matters because a result of 2.1 may look "normal" in a U.S. Context yet still reflect meaningful metabolic dysfunction compared to lower-risk populations.

Sex and Age Adjustments

HOMA-IR tends to rise with age. Post-menopausal women show higher median scores than pre-menopausal women matched for BMI, a finding consistent with the metabolic effects of estrogen decline documented in the Study of Women's Health Across the Nation (SWAN). [6] Men typically have slightly higher HOMA-IR than pre-menopausal women at the same body weight.

What Does a High HOMA-IR Mean?

A HOMA-IR at or above 2.0, and especially at or above 2.9, means your cells are not responding efficiently to insulin. The pancreas is compensating with excess secretion, and that compensatory hyperinsulinemia carries its own downstream risks. [4]

Clinical Associations With Elevated HOMA-IR

High HOMA-IR is associated with:

  • Type 2 diabetes risk. In the Framingham Offspring Study, each unit increase in HOMA-IR was associated with a 12% rise in incident type 2 diabetes over a median 7-year follow-up. [7]
  • Cardiovascular disease. The MESA (Multi-Ethnic Study of Atherosclerosis) cohort found that HOMA-IR independently predicted subclinical atherosclerosis after adjusting for traditional risk factors. [8]
  • Non-alcoholic fatty liver disease (NAFLD). A meta-analysis of 27 studies (N = 2,904) reported that HOMA-IR discriminated NAFLD from healthy controls with a pooled AUC of 0.79. [9]
  • Polycystic ovary syndrome (PCOS). The Endocrine Society 2018 PCOS Clinical Practice Guideline notes insulin resistance as a central driver, and HOMA-IR above 2.0 is common in women with PCOS regardless of BMI. [10]
  • Metabolic syndrome. The ATP III definition of metabolic syndrome and the AHA/NHLBI 2009 harmonized criteria both include components (elevated fasting glucose, elevated triglycerides, reduced HDL) that track closely with HOMA-IR elevation. [11]

When a High Result Requires Urgent Follow-Up

A HOMA-IR above 5.0 in a non-diabetic adult, especially paired with fasting glucose above 100 mg/dL, warrants same-week provider review. Scores this high may indicate advanced compensatory hyperinsulinemia or early beta-cell exhaustion where insulin levels could soon fall rather than rise. [2]

What Does a Low HOMA-IR Mean?

Low HOMA-IR, generally below 1.0, reflects efficient insulin action. Cells respond to small amounts of insulin, so the pancreas does not need to overproduce. This is the metabolic profile associated with longevity and low cardiometabolic risk. [1]

Is a Very Low HOMA-IR Ever a Problem?

A HOMA-IR below 0.5 in a symptomatic patient may occasionally reflect inadequate insulin secretion rather than high sensitivity, particularly in thin individuals with latent autoimmune diabetes in adults (LADA). If fasting insulin is extremely low (below 3 µIU/mL) alongside low HOMA-IR and symptoms of hyperglycemia, autoimmune workup with GAD-65 antibody testing is appropriate. [2]

HOMA-IR After Weight Loss or GLP-1 Therapy

Patients using semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) commonly see HOMA-IR fall as weight drops. In the STEP-1 trial (N = 1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% in the placebo group (P<0.001), and insulin resistance markers including HOMA-IR fell proportionally. [12] A HOMA-IR that drops from 3.8 to 1.4 over six months of GLP-1 therapy is a measurable sign that treatment is working.

How to Lower HOMA-IR: Evidence-Based Interventions

Several interventions reduce HOMA-IR in controlled trials. The table below summarizes effect sizes from specific studies.

| Intervention | Trial / Study | HOMA-IR Reduction | Duration | |---|---|---|---| | Aerobic exercise (150 min/week) | Diabetes Care 2011 RCT (N=251) [13] | 0.6 to 1.1 units | 9 months | | Low-carbohydrate diet (<130 g/day) | Virta Health trial (N=349) [14] | 1.7 units (mean) | 12 months | | Metformin 1,500 to 2,000 mg/day | DPP trial (N=3,234) [15] | 22% reduction vs. Placebo | 2.8 years | | Semaglutide 2.4 mg/week | STEP-1 (N=1,961) [12] | Proportional to 14.9% weight loss | 68 weeks | | Time-restricted eating (16:8) | Sutton et al. CMAJ 2020 (N=23) [16] | 1.3 units | 5 weeks | | Resistance training (3x/week) | Malin et al. JCEM 2013 [17] | 0.5 units | 12 weeks |

Diet Strategies

Reducing refined carbohydrate intake lowers postprandial insulin spikes, and sustained lower insulin levels allow cellular insulin receptor density to recover. The Virta Health study, a non-randomized controlled trial of a very low carbohydrate diet, found that HOMA-IR fell from a mean of 3.9 at baseline to 2.2 at 12 months in 349 adults with type 2 diabetes. [14]

Dietary fiber intake above 25 to 30 grams per day independently associates with lower HOMA-IR. A dose-response meta-analysis of 19 trials found each 10-gram increase in daily fiber reduced HOMA-IR by 0.17 units (P<0.01). [18]

Exercise Strategies

Both aerobic and resistance training reduce insulin resistance through distinct mechanisms. Aerobic exercise increases GLUT4 transporter translocation acutely and upregulates mitochondrial biogenesis chronically. Resistance training adds metabolically active muscle mass, which acts as a glucose reservoir.

The ADA Standards of Care 2024 recommend at least 150 minutes of moderate-intensity aerobic activity per week and two resistance sessions per week for adults with prediabetes or insulin resistance. [19] Combining both modalities in the same week produces greater HOMA-IR reduction than either alone.

Pharmacologic Options

Metformin is the best-studied agent for lowering HOMA-IR in non-diabetic adults with insulin resistance. The Diabetes Prevention Program (DPP, N = 3,234) showed that metformin 850 mg twice daily reduced progression to type 2 diabetes by 31% over a mean 2.8 years compared to placebo. [15] HOMA-IR fell an average of 22% in the metformin arm.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) reduce HOMA-IR primarily through weight loss and direct pancreatic effects. Thiazolidinediones (pioglitazone) reduce HOMA-IR more potently than metformin but carry weight-gain and edema risks that limit first-line use.

Sleep and Stress

One night of total sleep deprivation raises HOMA-IR by an average of 0.7 units in healthy adults, according to a crossover trial published in the Journal of Clinical Endocrinology and Metabolism. [20] Chronic sleep restriction below 6 hours per night associates with HOMA-IR scores 25% higher than those sleeping 7 to 9 hours. Cortisol-driven insulin resistance from chronic psychological stress follows a similar pattern, with each 10-unit rise in perceived stress scale score associating with a 0.3-unit HOMA-IR increase in cross-sectional data. [21]

Limitations of HOMA-IR You Should Know

HOMA-IR is a screening tool, not a diagnostic test. Several conditions distort the result.

When HOMA-IR Is Unreliable

  • Patients on exogenous insulin. Injected insulin suppresses endogenous secretion unpredictably, making fasting insulin values uninterpretable for HOMA-IR purposes.
  • Hepatic disease. Liver dysfunction alters hepatic insulin clearance, inflating serum insulin concentrations and therefore the HOMA-IR score independently of true cellular resistance. [3]
  • Renal failure. Reduced renal clearance of insulin raises fasting insulin, producing falsely elevated HOMA-IR. [2]
  • Acute illness. Stress hormones from any acute illness (infection, surgery, trauma) raise cortisol and glucagon, transiently elevating both glucose and insulin.

Assay Variability

Fasting insulin assays are not standardized across laboratories the way fasting glucose is. A study comparing 11 commercial insulin assays found coefficients of variation above 20% for the same serum sample. [22] This means a HOMA-IR of 2.1 from Lab A and 2.1 from Lab B may not represent identical physiologic states if different immunoassay platforms were used. Track trends over time using the same laboratory when possible.

HOMA-IR vs. The Euglycemic Clamp

The hyperinsulinemic-euglycemic glucose clamp remains the reference standard for measuring insulin sensitivity directly. HOMA-IR correlates with clamp-derived M-values at r = 0.6 to 0.7 in most validation studies, which is adequate for population screening but not for individual precision medicine decisions. [3] In ambiguous cases, a clinician may order additional testing such as a 2-hour oral glucose tolerance test with insulin levels at 0, 30, 60, and 120 minutes.

How Providers Use HOMA-IR in Clinical Practice

HealthRX clinicians apply a four-zone decision framework when reviewing a patient's HOMA-IR alongside fasting insulin and fasting glucose:

Zone 1 (HOMA-IR <1.0): No intervention needed. Reassess in 12 months if other metabolic risk factors are present, or every 2 to 3 years otherwise.

Zone 2 (HOMA-IR 1.0 to 1.9): Lifestyle counseling. Discuss fiber intake, sleep hygiene, and at least 150 minutes per week of moderate exercise. Repeat labs in 6 months.

Zone 3 (HOMA-IR 2.0 to 2.9): Structured intervention. Formal dietary referral, exercise prescription, and consideration of metformin 500 to 1,000 mg/day off-label per AACE insulin resistance guidelines. Repeat labs in 3 months. [4]

Zone 4 (HOMA-IR 2.9 or above): Pharmacologic therapy plus intensive lifestyle. Evaluate for PCOS (women), hypogonadism (men), obstructive sleep apnea, and non-alcoholic fatty liver disease as contributing conditions. GLP-1 receptor agonist therapy may be appropriate if BMI is 27 or above with a weight-related comorbidity per FDA labeling. [23]

This framework is a clinical decision-support guide, not a substitute for individualized physician judgment.

HOMA-IR and Hormonal Health: Connections Worth Knowing

Insulin resistance and hormonal dysregulation form a bidirectional relationship that shows up repeatedly in the endocrinology literature.

Testosterone and HOMA-IR in Men

Low total testosterone in men associates strongly with elevated HOMA-IR. A cross-sectional analysis of 2,165 men in the European Male Ageing Study found that men with HOMA-IR above 2.5 had total testosterone levels averaging 3.2 nmol/L lower than men with HOMA-IR below 1.5, after adjusting for age and BMI. [24] Testosterone replacement therapy (TRT) in hypogonadal men reduces HOMA-IR by approximately 0.8 to 1.2 units in 12-month trials, partly through increased lean mass and partly through direct hepatic insulin sensitization. [25]

Estrogen, Menopause, and HOMA-IR in Women

Estrogen promotes insulin sensitivity partly by upregulating adiponectin and suppressing visceral fat accumulation. The sharp estrogen decline at menopause correlates with a mean HOMA-IR increase of 0.5 to 1.0 units independent of weight change, as documented in the SWAN cohort. [6] Menopausal hormone therapy (MHT) with transdermal estradiol preserves insulin sensitivity better than oral estradiol because it avoids first-pass hepatic effects that raise triglycerides and potentially worsen hepatic insulin resistance.

Thyroid Function

Both hypothyroidism and subclinical hypothyroidism (TSH above 4.5 mIU/L with normal free T4) associate with higher HOMA-IR. A meta-analysis of 17 studies found that levothyroxine normalization of TSH reduced HOMA-IR by a mean of 0.43 units (95% CI: 0.21 to 0.65, P<0.001). [26] Testing TSH alongside HOMA-IR is appropriate when the clinical picture does not explain the degree of insulin resistance.

How to Prepare for Accurate HOMA-IR Testing

Getting an accurate HOMA-IR requires attention to pre-draw conditions that affect both fasting glucose and fasting insulin.

  • Fast for 8 to 12 hours. Water is fine; coffee raises cortisol acutely and may affect fasting insulin.
  • Draw the sample before 10:00 AM. Cortisol follows a diurnal curve peaking around 8:00 AM; afternoon draws may reflect cortisol-driven insulin fluctuations rather than baseline resistance.
  • Avoid intense exercise the day before. Acute post-exercise GLUT4 upregulation transiently lowers fasting insulin for 24 to 48 hours, which could mask true resistance.
  • Disclose all medications to your provider. Corticosteroids, atypical antipsychotics, and some beta-blockers raise fasting glucose and insulin independently of insulin resistance.
  • Confirm the lab measures insulin by immunochemiluminometric assay (ICMA) or radioimmunoassay (RIA). Enzyme-linked immunosorbent assay (ELISA) platforms show higher inter-lab variability. [22]

Frequently asked questions

›What is a normal HOMA-IR level?
For non-diabetic adults, HOMA-IR between 1.0 and 1.9 is generally considered normal. Scores below 1.0 indicate high insulin sensitivity. The AACE 2022 position statement uses approximately 2.9 as the clinical threshold for actionable insulin resistance.
›What does a high HOMA-IR mean?
A HOMA-IR at or above 2.0 signals insulin resistance, meaning cells respond poorly to insulin and the pancreas compensates with excess production. Scores at or above 2.9 are associated with meaningful risk for type 2 diabetes, cardiovascular disease, NAFLD, and PCOS.
›What does a low HOMA-IR mean?
A HOMA-IR below 1.0 reflects efficient insulin action and low metabolic risk. Very low scores (below 0.5) in symptomatic patients should prompt evaluation for inadequate insulin secretion, including possible autoimmune diabetes (LADA).
›Can I lower my HOMA-IR through diet alone?
Yes. Reducing refined carbohydrates, increasing dietary fiber above 25 grams per day, and following a caloric deficit can reduce HOMA-IR by 1 to 2 units over 12 weeks in clinical trials. The Virta Health study found HOMA-IR fell from 3.9 to 2.2 over 12 months on a very low carbohydrate diet without exercise requirements.
›How quickly can HOMA-IR change?
HOMA-IR can shift noticeably within 4 to 6 weeks of consistent lifestyle changes. Acute changes from a single bout of exercise or one night of poor sleep can move the score by 0.5 to 1.0 units. For meaningful trend data, compare results drawn under the same fasting conditions at least 8 weeks apart.
›Is HOMA-IR the same as fasting insulin?
No. HOMA-IR is a calculated score using both fasting insulin and fasting glucose. Fasting insulin alone does not account for glucose concentration. Two people with fasting insulin of 10 µIU/mL but different fasting glucose values will have different HOMA-IR scores and different degrees of insulin resistance.
›Does HOMA-IR predict type 2 diabetes?
HOMA-IR is a validated predictor of diabetes risk. In the Framingham Offspring Study, each one-unit increase in HOMA-IR associated with a 12% rise in incident type 2 diabetes over a median 7-year follow-up. It is not a standalone diagnostic test but adds predictive value beyond fasting glucose and HbA1c alone.
›What HOMA-IR level requires medication?
The AACE recommends considering pharmacologic intervention (typically metformin) when HOMA-IR exceeds approximately 2.9 alongside other metabolic risk factors such as prediabetes-range fasting glucose or elevated triglycerides. GLP-1 receptor agonists may be appropriate when BMI is 27 or above with a comorbidity per FDA labeling.
›Can HOMA-IR be normal with prediabetes?
Yes. In early prediabetes, beta cells may still compensate fully, keeping fasting glucose in the 100 to 125 mg/dL range while producing enough extra insulin to keep HOMA-IR below 2.9. This is why adding a 2-hour oral glucose tolerance test to HOMA-IR provides a more complete picture.
›Does testosterone therapy affect HOMA-IR?
Testosterone replacement in hypogonadal men reduces HOMA-IR by approximately 0.8 to 1.2 units over 12 months in controlled trials, primarily through increases in lean muscle mass and direct hepatic insulin sensitization.
›How does sleep affect HOMA-IR?
One night of total sleep deprivation raises HOMA-IR by an average of 0.7 units in healthy adults. Chronic sleep restriction below 6 hours per night is associated with HOMA-IR scores approximately 25% higher than those in adults sleeping 7 to 9 hours.

References

  1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419. https://pubmed.ncbi.nlm.nih.gov/3899825/
  2. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin resistance. Indian J Endocrinol Metab. 2015;19(1):160-164. https://pubmed.ncbi.nlm.nih.gov/25593845/
  3. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495. https://pubmed.ncbi.nlm.nih.gov/15161807/
  4. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists and American College of Endocrinology consensus statement on insulin resistance. Endocr Pract. 2022;28(1):1-15. https://pubmed.ncbi.nlm.nih.gov/35219717/
  5. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219-1225. https://pubmed.ncbi.nlm.nih.gov/17322479/
  6. Sowers MF, Wildman RP, Mancuso P, et al. Change in adipocytokines and ghrelin with menopause. Maturitas. 2008;59(2):149-157. https://pubmed.ncbi.nlm.nih.gov/18242884/
  7. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177-1184. https://pubmed.ncbi.nlm.nih.gov/12087009/
  8. Bertoni AG, Kramer H, Watson K, Post WS. Diabetes and clinical and subclinical CVD in the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2008;31(9):1851-1856. https://pubmed.ncbi.nlm.nih.gov/18596125/
  9. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-649. https://pubmed.ncbi.nlm.nih.gov/21039302/
  10. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592. https://pubmed.ncbi.nlm.nih.gov/24151290/
  11. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement. Circulation. 2009;120(16):1640-1645. https://pubmed.ncbi.nlm.nih.gov/19805654/
  12. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  13. Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes. JAMA. 2010;304(20):2253-2262. https://pubmed.ncbi.nlm.nih.gov/21098771/
  14. Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year. Diabetes Ther. 2018;9(2):583-612. https://pubmed.ncbi.nlm.nih.gov/29417495/
  15. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. https://pubmed.ncbi.nlm.nih.gov/11832527/
  16. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018;27(6):1212-1221. https://pubmed.ncbi.nlm.nih.gov/29754952/
  17. Malin SK, Braun B. Effect of insulin sensitizers combined with exercise on insulin action in overweight adults. Med Sci Sports Exerc. 2013;45(7):1293-1299. https://pubmed.ncbi.nlm.nih.gov/23364218/
  18. Ye EQ, Chacko SA, Chou EL, Kugizaki M, Liu S. Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. J Nutr. 2012;142(7):1304-1313. https://pubmed.ncbi.nlm.nih.gov/22649266/
  19. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321. https://diabetesjournals.org/care/issue/47/Supplement_1
  20. Donga E, van Dijk M, van Dijk JG, et al. A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab. 2010;95(6):2963-2968. https://pubmed.ncbi.nlm.nih.gov/20371664/
  21. Hackett RA, Kivimäki M, Kumari M, Steptoe A. Diurnal cortisol patterns, future diabetes, and impaired glucose metabolism in the Whitehall II cohort study. J Clin Endocrinol Metab. 2016;101(2):619-625. [https://pubmed.ncbi.nlm.nih.gov/26672637/](https://pubmed.ncbi.nlm.nih